Logo
x

Search

Subscribe Now

rinvoq

AbbVie's Rinvoq (upadacitinib) Receives EC's Approval for the Treatment of Moderate to Severe Atopic Dermatitis

AbbVie's Rinvoq (upadacitinib) Receives EC's Approval for the Treatment of Moderate to Severe Atopic Dermatitis

  • August 25, 2021
Insights+: The US FDA New Drug Approvals in August 2019

Insights+: The US FDA New Drug Approvals in August 2019

  • September 20, 2019
AbbVie’s Rinvoq (upadacitinib) Receives the US FDA’s Approval for the Treatment of Adults with Moderately to Severely Active Crohn

    AbbVie’s Rinvoq (upadacitinib) Receives the US FDA’s Approval for the Treatment of Adults with Moderately to Severely Active Crohn...

    • May 19, 2023
    AbbVie’s Rinvoq (upadacitinib) Receives EC’s Approval for the Treatment of Moderately to Severely Active Crohn

      AbbVie’s Rinvoq (upadacitinib) Receives EC’s Approval for the Treatment of Moderately to Severely Active Crohn's Disease

      • April 17, 2023
      Insights+: EMA Marketing Authorization of New Drugs in February 2023

        Insights+: EMA Marketing Authorization of New Drugs in February 2023

        • March 23, 2023
        AbbVie Receives EMA’s CHMP Positive Opinion of Rinvoq (upadacitinib) for Crohn

          AbbVie Receives EMA’s CHMP Positive Opinion of Rinvoq (upadacitinib) for Crohn's Disease

          • February 27, 2023
          AbbVie’s Rinvoq (upadacitinib) Receives NICE Recommendation for the Treatment of Active Ulcerative Colitis

            AbbVie’s Rinvoq (upadacitinib) Receives NICE Recommendation for the Treatment of Active Ulcerative Colitis

            • November 25, 2022
            AbbVie’s Rinvoq (upadacitinib) Receives EC’s Approval as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

              AbbVie’s Rinvoq (upadacitinib) Receives EC’s Approval as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloa...

              • July 29, 2022
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.